Every material Form 8-K Clorox filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
The Clorox Company reported its first-quarter fiscal 2027 results, showing a 33% increase in net sales to $1.91 billion and a diluted net earnings per share of $1.39. While maintaining its fiscal year 2027 full-year net sales and adjusted EPS ranges, the company expects adjusted EPS results closer to the low end due to higher inflationary pressures and commodity costs.
Net sales increased 33% to $1.91 billion, with organic sales up 18%.
Diluted EPS increased 114% to $1.39 compared to $0.65 in the year-ago quarter.
Adjusted EPS increased 82% to $1.55 compared to $0.85 in the year-ago quarter.
Full-year fiscal 2027 diluted EPS is expected to be between $5.41 and $5.71, with adjusted EPS expected between $5.70 and $6.00.
The Clorox Company's board appointed Fabian Garcia, currently president of Unilever Personal Care, as chief executive officer effective January 5, 2027. Linda Rendle steps down as CEO and chair on that date and will serve as a senior advisor through April 2, 2027, while Matthew Shattock becomes independent chair. The filing lists Garcia's offer terms, including a $100,000 base salary and an $11,000,000 sign-on RSU award, and the company's first-quarter fiscal 2027 earnings are scheduled for November 2.
Fabian Garcia appointed CEO effective January 5, 2027; he will also join the board
Linda Rendle steps down as CEO and director on January 5, 2027, and advises through April 2, 2027
Matthew Shattock to become independent chair, with a $225,000 chair retainer
Garcia's offer letter includes a $100,000 base salary, $2,000,000 target annual bonus and $11,000,000 one-time sign-on RSU award
Clorox reported fourth-quarter and fiscal 2026 results on August 3, 2026, with net sales down 2% to $1.95 billion and diluted EPS down 50% to $1.34, as lapping ERP-related shipments and GOJO acquisition costs weighed on results. For fiscal 2027 the company expects net sales to rise 13% to 14%, including about 9.5 points from the GOJO acquisition, and diluted EPS of $5.41 to $5.71, while describing the operating environment as challenging.
Q4 net sales decreased 2% to $1.95 billion; GOJO added about 10 points, while organic sales decreased 13%.
Q4 diluted EPS was $1.34 versus $2.68 a year earlier; adjusted EPS was $1.66 versus $2.87.
Fiscal 2026 net sales fell 5% to $6.72 billion and diluted EPS fell 26% to $4.81; operating cash flow was $612 million versus $981 million.
Fiscal 2027 outlook: adjusted EPS of $5.70 to $6.00, and gross margin of about 42%.
Clorox appointed Chris Hyder as executive vice president and chief operating officer and Nina Barton as executive vice president and chief growth and strategy officer, both effective June 17, 2026, as part of a simplified operating structure. The company also said its board is running a search for a new CEO, which it first announced on May 28.
Chris Hyder named EVP and chief operating officer effective June 17, 2026, with base salary raised to $800,000 and short-term incentive target raised from 90% to 100%
Hyder to receive restricted stock units with an aggregate fair value of $4,000,000, vesting in three years
Nina Barton moves to EVP and chief growth and strategy officer; commercial functions will report to her role
Board is undertaking a comprehensive search with a leading firm for a new CEO, as announced May 28
Clorox said Chair and CEO Linda Rendle asked the Board to begin a CEO search, citing a decision to step down for health reasons. She will remain Chair and CEO until a successor is appointed and will then serve in an advisory role for a period. The filing does not include financial results or guidance changes, but the leadership transition is significant for shareholders.
Linda Rendle asked the Board on May 26, 2026 to start a CEO search process, citing health reasons.
Rendle remains Chair and CEO during the search and until a new CEO is appointed.
The search is led by an independent committee with a leading executive search firm.
Rendle and CFO Luc Bellet will join a fireside chat at the dbAccess Global Consumer Conference on June 3 in Paris.
Clorox reported third-quarter fiscal 2026 results for the quarter ended March 31, 2026, with net sales flat at $1.67 billion and adjusted EPS up 13% to $1.64. The company lowered its full-year outlook, now expecting adjusted EPS of $5.45 to $5.65 versus a prior range of $5.95 to $6.30, and gross margin down 250 to 300 basis points, which weighs on shareholder value expectations for the year.
Q3 net sales were $1.67 billion, flat year over year; organic sales decreased 1%; gross margin fell 140 basis points to 43.2%.
Q3 adjusted EPS rose 13% to $1.64; diluted EPS rose 3% to $1.54.
Full-year fiscal 2026 adjusted EPS outlook is $5.45 to $5.65, a decline of 27% to 29%, versus a prior range of $5.95 to $6.30; net sales are now expected to fall about 6%.
The GOJO Industries acquisition closed April 1, 2026; an inventory draw-down tied to the ERP transition is expected to reduce fiscal 2026 EPS by about 90 cents.
Clorox entered two credit agreements on March 6, 2026, totaling $2.25 billion, in connection with its purchase of GOJO Industries, maker of PURELL. The $1.25 billion delayed draw term loan is designed to help finance part of the acquisition price, so the company will take on new senior unsecured debt if the deal closes.
364-day revolving credit agreement of $1 billion, with borrowings available until March 5, 2027
Delayed draw term credit agreement of $1.25 billion, to fund part of the GOJO acquisition consideration
Delayed draw commitments terminate on the earliest of December 31, 2026, termination of the acquisition agreement, or closing without using this financing
Clorox reported second-quarter fiscal 2026 results for the period ended December 31, 2025, with net sales down 1% to $1.67 billion and diluted EPS down 16% to $1.29. The company kept its full-year outlook but said results are tracking toward the lower end of the range because of order fulfillment challenges, an inventory drawdown, and higher costs.
Net sales fell 1% to $1.67 billion; organic sales also fell 1%, driven by lower consumption.
Diluted EPS fell 16% to $1.29 from $1.54; adjusted EPS fell 10% to $1.39 from $1.55.
Full-year fiscal 2026 guidance was maintained: diluted EPS of $5.60 to $5.95 and adjusted EPS of $5.95 to $6.30, both at the lower end of the range.
Household segment adjusted EBIT fell 54%; International segment adjusted EBIT rose 48%.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Clorox filing is on SEC EDGAR ↗. 8-K briefs of other companies →